Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

Choi KY, Sharon B, Balfour HH Jr, Belani K, Pozos TC, Schleiss MR.

J Clin Virol. 2013 Aug;57(4):356-60. doi: 10.1016/j.jcv.2013.04.004. Epub 2013 May 18.

2.

Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection.

Campanini G, Zavattoni M, Cristina E, Gazzolo D, Stronati M, Baldanti F.

J Clin Virol. 2012 May;54(1):86-8. doi: 10.1016/j.jcv.2012.01.020. Epub 2012 Feb 28.

PMID:
22381918
3.

Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection.

Yilmaz Çiftdogan D, Vardar F.

J Trop Pediatr. 2011 Apr;57(2):132-4. doi: 10.1093/tropej/fmq050. Epub 2010 Jun 24.

PMID:
20576693
4.

Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.

Meine Jansen CF, Toet MC, Rademaker CM, Ververs TF, Gerards LJ, van Loon AM.

J Perinat Med. 2005;33(4):364-6.

PMID:
16211780
5.

Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening.

Kawada J, Torii Y, Kawano Y, Suzuki M, Kamiya Y, Kotani T, Kikkawa F, Kimura H, Ito Y.

J Clin Virol. 2015 Apr;65:41-5. doi: 10.1016/j.jcv.2015.01.015. Epub 2015 Jan 23.

PMID:
25766986
6.

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.

Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A.

Antivir Ther. 2009;14(5):697-704.

PMID:
19704173
7.

Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection.

Stronati M, Lombardi G, Garofoli F, Villani P, Regazzi M.

Curr Drug Metab. 2013 Feb;14(2):208-15. Review.

PMID:
22935067
8.

Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.

Sánchez Puch S, Ochoa C, Carballal G, Zala C, Cahn P, Brunet R, Salomón H, Videla C.

J Clin Virol. 2004 Jul;30(3):271-5.

PMID:
15135748
9.

Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.

Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, Vernant JP, Gandjbakhch I, Imbert-Marcille BM, Agut H.

Antiviral Res. 2009 Feb;81(2):174-9. doi: 10.1016/j.antiviral.2008.11.003. Epub 2008 Dec 6.

PMID:
19063923
10.

Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.

Martin M, Goyette N, Ives J, Boivin G.

J Clin Virol. 2010 Apr;47(4):321-4. doi: 10.1016/j.jcv.2010.01.009. Epub 2010 Feb 6.

PMID:
20138805
11.

Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence.

Sun J, Cao G, Zhang L, Zhang Y, Zhao Z, Hu J, Ji Y.

Transplant Proc. 2012 Dec;44(10):3022-5. doi: 10.1016/j.transproceed.2012.06.069.

PMID:
23195018
12.

Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.

Iwasenko JM, Scott GM, Rawlinson WD, Keogh A, Mitchell D, Chou S.

J Med Virol. 2009 Mar;81(3):507-10. doi: 10.1002/jmv.21397.

13.

Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.

Peixoto M, Mascarenhas L, Cunha A, Dutra M, Miranda E, Silva I, Costa S, Galvão B, Cunha A.

Antivir Ther. 2012;17(3):585-8. doi: 10.3851/IMP1938. Epub 2011 Oct 27.

PMID:
22293247
14.

Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.

Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V.

J Antimicrob Chemother. 2009 Mar;63(3):600-8. doi: 10.1093/jac/dkn521. Epub 2009 Jan 15.

PMID:
19147520
15.

Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.

Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM.

Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9.

PMID:
20002612
16.

Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.

Drew WL, Liu C.

Clin Transplant. 2012 Nov-Dec;26(6):949-52. doi: 10.1111/j.1399-0012.2012.01681.x. Epub 2012 Jul 9.

PMID:
22774759
17.

Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.

García-Martínez J, Folgueira L, Delgado R, Hernando S, Prieto C, Aguado JM, Otero JR.

Transpl Infect Dis. 2008 Apr;10(2):123-8. Epub 2007 Jul 1.

PMID:
17605746
18.

Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.

Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison MG.

Transpl Infect Dis. 2016 Jun;18(3):390-5. doi: 10.1111/tid.12537. Epub 2016 Jun 9.

PMID:
27037651
19.

Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.

Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL.

J Clin Virol. 2007 Feb;38(2):120-5. Epub 2006 Dec 8.

PMID:
17157554
20.

Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.

Amir J, Wolf DG, Levy I.

Eur J Pediatr. 2010 Sep;169(9):1061-7. doi: 10.1007/s00431-010-1176-9. Epub 2010 Mar 16.

PMID:
20232081

Supplemental Content

Support Center